Stocksigma LogoStocksigma Logo

OneSource Reports Strong Q2FY27 Growth Driven by DDC Capacity and Commercial Launches

OneSource Specialty Pharma reported Q2FY27 revenue of ₹5,162m, up 37% YoY and 15% QoQ, driven by new Drug-Device Combination (DDC) capacity, robust MSA

OneSource Reports Strong Q2FY27 Growth Driven by DDC Capacity and Commercial Launches

Onesource Specialty Pharma Ltd · Press Release · 27 Oct 2026, 4:16 pm

OneSource Reports Strong Q2FY27 Growth Driven by DDC Capacity and Commercial Launches OneSource Specialty Pharma reported Q2FY27 revenue of ₹5,162m, up 37% YoY and 15% QoQ, driven by new Drug-Device Combination (DDC) capacity, robust MSA execution, and 12 product launches. EBITDA surged 53% YoY and 32% QoQ to ₹1,633m, with margins expanding 329 bps YoY to 31.6% via operating leverage. Adjusted PAT rose 109% YoY to ₹937m, delivering an adjusted EPS of ₹8.2. Operational momentum included commercializing a second cartridge line and onboarding a US biologics partner. Management reaffirmed its FY28 outlook of $400m organic revenue with 40% steady-state EBITDA margins.

Original exchange filing (PDF)

More announcements from Onesource Specialty Pharma Ltd

All Onesource Specialty Pharma Ltd announcements